TIE2 Activation for the Treatment of Chemical-Induced Acute Lung Injury
TIE2 激活治疗化学引起的急性肺损伤
基本信息
- 批准号:9352549
- 负责人:
- 金额:$ 46.2万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2017
- 资助国家:美国
- 起止时间:2017-08-15 至 2020-07-31
- 项目状态:已结题
- 来源:
- 关键词:ANGPT1 geneAcuteAcute Lung InjuryAdult Respiratory Distress SyndromeAgonistAlbuminsAlveolarAngiopoietin-2Biological AssayBlood VesselsBlood capillariesBreathingBronchoalveolar Lavage FluidCell CountCessation of lifeChemicalsChloridesClinicalDevelopmentDoseEndothelial CellsExploratory/Developmental Grant for Diagnostic Cancer ImagingExposure toExtravasationFunctional disorderGasesGoalsHistamineHumanIn VitroInbred MouseInbred Strains MiceInbreedingIndustrializationInflammationInjuryLeadLigandsLiquid substanceLungMedicalModelingMouse StrainsMusNosePathologicPharmaceutical PreparationsPharmacologyPhosgenePopulationPre-Clinical ModelPreventionProteinsPulmonary EdemaReceptor Protein-Tyrosine KinasesSecondary toSepsisSerotoninSignal TransductionSpecificitySyndromeTEK geneTestingTherapeuticTimeTranslatingTreatment EfficacyVascular Endothelial Growth FactorsVascular PermeabilitiesWorkcapillarychemical threatcohorteffective therapyin vivoinhibitor/antagonistmicroCTmortalitymouse modelnovelphosphatase inhibitorpreventrespiratoryscreeningsexsmall molecule inhibitortoxic industrial chemicalvascular endothelial protein tyrosine phosphatase
项目摘要
Phosgene (carbonyl chloride, COCl2) is a toxic industrial chemical that causes alveolar injury, resulting in acute
pulmonary edema and fatal acute respiratory distress syndrome. No effective therapy currently exists to treat
phosgene-induced acute lung injury (ALI), and it is considered a significant chemical threat. Pulmonary edema
results from a disruption of alveolar capillary endothelial barrier function. A critical regulator of such barrier
function is the endothelial receptor tyrosine kinase Tie2. Tie2 activation by its agonist ligand, angiopoietin-1
(ANG-1), promotes vascular integrity, thereby preventing vascular leak induced by inflammation and other
factors. In contrast, ANG-2, which acts primarily as a Tie2 antagonist, promotes vascular leak in a variety of
pathological conditions. Importantly, ANG-2 expression is increased in phosgene-induced ALI, suggesting that
decreased Tie2 activity is an important factor in phosgene-induced pulmonary edema. In addition to ANG-2,
Tie2 is negatively regulated by vascular endothelial-protein tyrosine phosphatase (VE-PTP). Our group has
developed highly selective small molecule inhibitors of VE-PTP, which dramatically increase Tie2 activity and
promote endothelial barrier function in multiple preclinical models. Our preliminary studies demonstrate that
one such VE-PTP inhibitor, AKB-9785, significantly reduces vascular permeability and mortality in a mouse
model of phosgene-induced ALI, suggesting that this novel class of compounds could be effective treatments
for pulmonary edema secondary to inhalation of phosgene and other alveolar-targeted toxic industrial gases. In
work performed under our recent CounterACT R21 award, we have made significant progress in identifying
therapeutics for the above clinical syndromes. Specifically, we have: 1) developed a nose-only mouse
exposure model of phosgene-induced ALI that allows us to study and treat the respiratory effects of phosgene
inhalation; 2) identified potent, selective VE-PTP inhibitors/Tie2 activators through in vitro screening; 3)
validated VE-PTP inhibition as an effective therapeutic for reducing pulmonary vascular leak after phosgene
inhalation; and 4) demonstrated preliminary efficacy of VE-PTP inhibition in the reduction of phosgene
inhalation-induced mortality. The central hypothesis of this proposal is that pharmacological activation of
Tie2 using highly selective and potent small molecule inhibitors of VE-PTP will prevent phosgene-
induced vascular leak, pulmonary edema, and mortality. Accordingly, the Specific Aims of this proposal
are to: 1) Identify the most potent VE-PTP inhibitors with the greatest efficacy in vitro and in vivo; 2)
Demonstrate that VE-PTP inhibitors prevent phosgene-induced pulmonary vascular leak and reduce markers
of acute lung injury; and 3) Identify the best VE-PTP inhibitor that successfully inhibits phosgene-induced
mortality. Accomplishing these Specific Aims is expected to lead to the identification of drugs that can be
rapidly translated into effective therapies for the treatment of ALI induced by phosgene and other alveolar-
targeted toxic industrial gases.
光气(COCl2)是一种有毒的工业化学品,会导致肺泡损伤,导致急性
肺水肿和致命性急性呼吸窘迫综合征。目前还没有有效的治疗方法
光气诱导的急性肺损伤(ALI),被认为是一种重大的化学威胁。肺水肿
肺泡毛细血管内皮细胞屏障功能受损所致。这一障碍的关键调节者
功能是内皮受体酪氨酸激酶Tie2。Tie2的激动剂配体血管生成素-1激活Tie2
(Ang-1),促进血管完整性,从而防止因炎症和其他原因导致的血管泄漏
各种因素。相反,主要作为Tie2拮抗剂的Ang-2促进多种血管渗漏。
病理情况。重要的是,Ang-2在光气诱导的ALI中表达增加,提示
Tie2活性降低是光气性肺水肿的重要因素。除了血管紧张素-2,
Tie2受血管内皮细胞酪氨酸磷酸酶(VE-PTP)负调控。我们的团队已经
开发了高选择性的VE-PTP小分子抑制剂,显著提高了Tie2的活性和
在多种临床前模型中促进内皮屏障功能。我们的初步研究表明
一种这样的VE-PTP抑制剂AKB-9785显著降低了小鼠的血管通透性和死亡率
光气诱导的ALI模型,提示这类新化合物可能是有效的治疗方法
用于吸入光气和其他以肺泡为靶标的有毒工业气体而导致的继发性肺水肿。在……里面
根据我们最近的反R21奖所做的工作,我们在确定
治疗上述临床症状。具体地说,我们已经:1)开发了一种只有鼻子的老鼠
光气性ALI暴露模型的建立及光气呼吸效应的研究
吸入;2)通过体外筛选确定有效的、选择性的VE-PTP抑制剂/Tie2激活剂;3)
证实VE-PTP抑制是减少光气后肺血管漏的有效治疗方法
4)显示VE-PTP抑制光气减少的初步效果
吸入性死亡。这一提议的中心假设是,药物激活
Tie2使用高选择性和强大的VE-PTP小分子抑制剂将阻止光气-
导致血管渗漏、肺水肿和死亡。因此,这项提案的具体目标是
目的是:1)确定体外和体内效果最好的VE-PTP抑制剂;2)
证明VE-PTP抑制剂可预防光气引起的肺血管渗漏并减少标志物
3)确定成功抑制光气诱导的最佳VE-PTP抑制剂
死亡率。实现这些具体目标有望导致识别出可以
迅速转化为治疗光气性和其他肺泡性ALI的有效疗法。
瞄准有毒工业气体。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Christopher D Kontos其他文献
Christopher D Kontos的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Christopher D Kontos', 18)}}的其他基金
Medical Scientist Training Program Training Grant
医学科学家培训计划培训补助金
- 批准号:
10411303 - 财政年份:2022
- 资助金额:
$ 46.2万 - 项目类别:
Medical Scientist Training Program Training Grant
医学科学家培训计划培训补助金
- 批准号:
10647684 - 财政年份:2022
- 资助金额:
$ 46.2万 - 项目类别:
TIE2 Activation for the Treatment of Chemical-Induced Acute Lung Injury
TIE2 激活治疗化学引起的急性肺损伤
- 批准号:
9753248 - 财政年份:2017
- 资助金额:
$ 46.2万 - 项目类别:
Skeletal Muscle and Vascular Remodeling in Peripheral Artery Disease
周围动脉疾病中的骨骼肌和血管重塑
- 批准号:
9335975 - 财政年份:2015
- 资助金额:
$ 46.2万 - 项目类别:
Skeletal Muscle and Vascular Remodeling in Peripheral Artery Disease
周围动脉疾病中的骨骼肌和血管重塑
- 批准号:
8887762 - 财政年份:2015
- 资助金额:
$ 46.2万 - 项目类别:
Skeletal Muscle and Vascular Remodeling in Peripheral Artery Disease
周围动脉疾病中的骨骼肌和血管重塑
- 批准号:
8903576 - 财政年份:2014
- 资助金额:
$ 46.2万 - 项目类别:
Muscle-Resident Stem Cells for Angiogenesis and Vascular Maturation in PAD
用于 PAD 血管生成和血管成熟的肌肉驻留干细胞
- 批准号:
8707552 - 财政年份:2013
- 资助金额:
$ 46.2万 - 项目类别:
相似海外基金
Combinatorial cytokine-coated macrophages for targeted immunomodulation in acute lung injury
组合细胞因子包被的巨噬细胞用于急性肺损伤的靶向免疫调节
- 批准号:
10648387 - 财政年份:2023
- 资助金额:
$ 46.2万 - 项目类别:
Lung epithelial cell-derived C3 in acute lung injury
肺上皮细胞衍生的 C3 在急性肺损伤中的作用
- 批准号:
10720687 - 财政年份:2023
- 资助金额:
$ 46.2万 - 项目类别:
Examining the role of TRMT1 and tRNA methylation in acute lung injury and ARDS
检查 TRMT1 和 tRNA 甲基化在急性肺损伤和 ARDS 中的作用
- 批准号:
10719249 - 财政年份:2023
- 资助金额:
$ 46.2万 - 项目类别:
Inducible HMGB1 antagonist for viral-induced acute lung injury.
诱导型 HMGB1 拮抗剂,用于治疗病毒引起的急性肺损伤。
- 批准号:
10591804 - 财政年份:2023
- 资助金额:
$ 46.2万 - 项目类别:
MAP2K1 AND MAP2K2 IN ACUTE LUNG INJURY AND RESOLUTION
MAP2K1 和 MAP2K2 在急性肺损伤中的作用及缓解
- 批准号:
10741574 - 财政年份:2023
- 资助金额:
$ 46.2万 - 项目类别:
Development of a new treatment for COVID-19-related acute lung injury targeting the microbiota-derived peptide corisin
针对微生物群衍生肽 corisin 开发治疗 COVID-19 相关急性肺损伤的新疗法
- 批准号:
23K07651 - 财政年份:2023
- 资助金额:
$ 46.2万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Probing immunovascular mechanobiology in pneumonia-associated acute lung injury at the single capillary level
在单毛细血管水平探讨肺炎相关急性肺损伤的免疫血管力学生物学
- 批准号:
10679944 - 财政年份:2023
- 资助金额:
$ 46.2万 - 项目类别:
The amyloid precursor protein protects against acute lung injury
淀粉样前体蛋白可预防急性肺损伤
- 批准号:
10575258 - 财政年份:2023
- 资助金额:
$ 46.2万 - 项目类别:
Role of macrophages and miRNA in regulating lung macrophage polarization and lung pathogenesis during respiratory virus-induced acute lung injury in normal and diabetic Syrian hamsters.
正常和糖尿病叙利亚仓鼠呼吸道病毒引起的急性肺损伤期间巨噬细胞和 miRNA 在调节肺巨噬细胞极化和肺部发病机制中的作用。
- 批准号:
10701207 - 财政年份:2023
- 资助金额:
$ 46.2万 - 项目类别:
Identification of novel phenotypes of acute lung injury using multimodal longitudinal data
使用多模态纵向数据识别急性肺损伤的新表型
- 批准号:
MR/Y000404/1 - 财政年份:2023
- 资助金额:
$ 46.2万 - 项目类别:
Fellowship